Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The role of glutathione-S-transferase in anti-cancer drug resistance

Abstract

Glutathione-S-transferases (GSTs) are a family of Phase II detoxification enzymes that catalyse the conjugation of glutathione (GSH) to a wide variety of endogenous and exogenous electrophilic compounds. GSTs are divided into two distinct super-family members: the membrane-bound microsomal and cytosolic family members. Microsomal GSTs are structurally distinct from the cytosolic in that they homo- and heterotrimerize rather than dimerize to form a single active site. Microsomal GSTs play a key role in the endogenous metabolism of leukotrienes and prostaglandins. Human cytosolic GSTs are highly polymorphic and can be divided into six classes: α, μ, ω, π, θ, and ζ. The π and μ classes of GSTs play a regulatory role in the mitogen-activated protein (MAP) kinase pathway that participates in cellular survival and death signals via protein : protein interactions with c-Jun N-terminal kinase 1 (JNK1) and ASK1 (apoptosis signal-regulating kinase). JNK and ASK1 are activated in response to cellular stress. GSTs have been implicated in the development of resistance toward chemotherapy agents. It is plausible that GSTs serve two distinct roles in the development of drug resistance via direct detoxification as well as acting as an inhibitor of the MAP kinase pathway. The link between GSTs and the MAP kinase pathway provides a rationale as to why in many cases the drugs used to select for resistance are neither subject to conjugation with GSH, nor substrates for GSTs. GSTs have emerged as a promising therapeutic target because specific isozymes are overexpressed in a wide variety of tumors and may play a role in the etiology of other diseases, including neurodegenerative diseases, multiple sclerosis, and asthma. Some of the therapeutic strategies so far employed are described in this review.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  • Adler V, Yin Z, Fuchs SY, Benerza M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ and Ronai Z . (1999). EMBO J., 18, 1321–1334.

  • Baez S, Segura-Aguilar J, Widersten M, Johansson AS and Mannervik B . (1997). Biochem. J., 324 (Part 1), 25–28.

  • Bakker J, Lin X and Nelson WG . (2002). J. Biol. Chem., 277, 22573–22580.

  • Black SM, Beggs JD, Hayes JD, Bartoszek A, Muramatsu M, Sakai M and Wolf CR . (1990). Biochem. J., 268, 309–315.

  • Brown GL, Lum RT, Schow SR, Maack C, Vollmer C, Gomez R, Delioukina M, Boulos L, Laxa B, Brown J and Rosen LS . (2001). TLK286: phase I dose escalation trial in patients with advanced malignancies.

  • Capron A, Capron M, Dombrowicz D and Riveau G . (2001). Int. Arch. Allergy Immunol., 124, 9–15.

  • Capron A, Riveau G, Grzych JM, Boulanger D, Capron M and Pierce R . (1995). Mem. Inst. Oswaldo Cruz, 90, 235–240.

  • Carver-Moore K, Broxmeyer HE, Luoh SM, Cooper S, Peng J, Burstein SA, Moore MW and de Sauvage FJ . (1996). Blood, 88, 803–808.

  • Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, Eom SJ, Kim MJ, Chang TS, Choi SY, Shim J, Kim Y, Dong MS, Lee MJ, Kim SG, Ichijo H and Choi EJ . (2001). J. Biol. Chem., 276, 12749–12755.

  • Clapper ML, Hoffman SJ and Tew KD . (1990). J. Cell. Pharmacol., 1, 71–78.

  • Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ and Buchwald M . (2001). Nat. Med., 7, 814–820.

  • Danielson UH and Mannervik B . (1985). Biochem. J., 231, 263–267.

  • Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH and Becker K . (2001). J. Med. Chem., 44, 4268–4276.

  • Davis RJ . (2000). Cell, 103, 239–252.

  • DeCampo R and Moreno SNJ . (1984). Free Radic. Biol., VI, 243–288.

  • Dorion S, Lambert H and Landry J . (2002). J. Biol. Chem., 34, 30792–30797.

  • Fan M and Chambers TC . (2001). Drug Resist. Updat., 4, 253–267.

  • Ford JM, Hait WN, Matlin SA and Benz CC . (1991). Cancer Lett., 56, 85–94.

  • Gunnarsdottir S and Elfarra AA . (1999). J. Pharmacol. Exp. Ther., 290, 950–957.

  • Hall A, Robson CN, Hickson ID, Harris AL, Proctor SJ and Cattan AR . (1989). Cancer Res., 49, 6265–6268.

  • Harwaldt P, Rahlfs S and Becker K . (2002). Biol. Chem., 383, 821–830.

  • Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ and Wolf CR . (1998). Proc. Natl. Acad. Sci. USA, 95, 5275–5280.

  • Ichijo H, Nshida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y . (1997). Science, 275, 90–94.

  • Izbicka E, Lawrence R, Cerna C, Von Hoff DD and Sanderson PE . (1997). Anticancer Drugs, 8, 345–348.

  • Kauvar KM . (1996). Glutathione-S-Transferases Structure, Function and Clinical Implications. Van Bladeren PJ (ed). Taylor & Francis: London, pp. 187–198.

    Google Scholar 

  • Kauvar LM, Morgan AS, Sanderson PE and Henner WD . (1998). Chem. Biol. Interact., 111-112, 225–238.

  • Kavanagh JJ, Spriggs D, Bookman M, Ozols R, Gershenson DM, Han J, Lewis L, Brown GL, Dombrowski J, Maack C, Macpherson J, Lane A, Woodrow P and Henner WD . (2002). Eur. J. Cancer. ASCO. Abstract 831.

  • Kodym R, Calkins P and Story M . (1999). J. Biol. Chem., 274, 5131–5137.

  • Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB and Nelson WG . (1994). Proc. Natl. Acad. Sci. USA, 91, 11733–11737.

  • Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM and Nelson WG . (2001). Am. J. Pathol., 159, 1815–1826.

  • Litwack G, Ketterer B and Arias IM . (1971). Nature, 234, 466–467.

  • Lyttle MH, Docker MD, Hui HC, Caldwell CG, Aaron DT, Engqvist-Goldstein A, Flatgaard JE and Bauer KE . (1994a). J. Med. Chem., 37, 189–194.

  • Lyttle MH, Satyam A, Hocker MD, Bauer KE, Caldwell CG, Hui HC, Morgan AS, Mergia A and Kauvar LM . (1994b). J. Med. Chem, 37, 1501–1507.

  • Mapp CE, Fryer AA, De Marzo N, Pozzato V, Padoan M, Boschetto P, Strange RC, Hemmingsen A and Spiteri MA . (2002). J. Allergy Clin. Immunol., 109, 867–872.

  • McLellan LI and Wolf CR . (1999). Drug Resist. Updat., 2, 153–164.

  • Morgan AS, Ciaccio PJ, Tew KD and Kauvar LM . (1996). Cancer Chemother. Pharmacol., 37, 363–370.

  • Morgan AS, Sanderson PE, Borch RF, Tew KD, Niktsu Y, Takayana T, VonHoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner DW and Kauvar LM . (1998). Cancer Res., 58, 2568–2575.

  • Mulder TP, Peters WH, Wobbes T, Witteman BJ and Jansen JB . (1997). Cancer, 80, 873–880.

  • Nare B, Smith JM and Prichard RK . (1992). Biochem. Pharmacol., 43, 1345–1351.

  • Oakley AJ, Lo Bello M, Mazzetti AP, Federici G and Parker MW . (1997). FEBS Lett., 419, 32–36.

  • O'Brien ML, Vulevic B, Freer S, Boyd J, Shen H and Tew KD . (1999). J. Pharmacol. Exp. Ther., 291, 1348–1355.

  • O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S and Comis RL (1991). Cancer Res., 51, 6059–6065.

  • Ono K and Han J . (2000). Cell Signal., 12, 1–13.

  • Papadimitrakopoulou V, Figlin R, Garland L, Von Hoff D, Kris M, Purdom M, Brown GL, Maack C, Macpherson J and Henner WD . (2003). Eur. J. Cancer. ASCO. Abstract 2636.

  • Petrini M, Conte A, Caracciolo F, Sabbatini A, Grassi B and Ronca G . (1993). Br. J. Haematol., 85, 409–410.

  • Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R and Mercola D . (1997). J. Biol. Chem., 272, 14041–14044.

  • Ranson H, Prapanthadara L and Hemingway J . (1997). Biochem. J., 324 (Part 1), 97–102.

  • Rosario LA, O'Brien ML, Henderson CJ, Wolf CR and Tew KD . (2000). Mol. Pharmacol., 58, 167–174.

  • Rosen LS, Brown J, Laxa B, Boylos L, Reiswig L, Henner WD, Lum RT, Schow SR, Maack CA, Keck JG, Mascavage JC, Dombroski JA, Gomez RF, and Brown GL . (2003). Clinical Cancer Research, 9, 1628–1638.

  • Ruscoe JE, Rosario LA, Wang T, Gate L, Arifoglu P, Wolf CR, Henderson CJ, Ronai Z and Tew KD . 2001. J. Pharmacol. Exp. Ther., 298, 339–345.

  • Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono, K and Ichijo H . (1998). EMBO J., 17, 2596–2606.

  • Schisselbauer JC, Silber R, Papadoupoulos E, Abrams K, LaCreta FP and Tew KD . (1990). Cancer Res., 50, 3569–3673.

  • Shen H, Tsuchida S, Tamai K and Sato K . (1993). Arch. Biochem. Biophys., 300, 137–141.

  • Tang AH and Tu CP . (1994). J. Biol. Chem., 269, 27876–27884.

  • Tew KD . (1994). Cancer Res., 54, 4313–4320.

  • Tew KD, Bomber AM and Hoffman SJ . (1988). Cancer Res., 48, 3622–3625.

  • Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, Wheatley JB and Schmidt Jr DE . (1996). Mol. Pharmacol., 50, 149–159.

  • Tipping E, Ketterer B and Koskelo P . (1978). Biochem. J., 169, 509–516.

  • Tobiume K, Saitoh M and Ichijo H . (2002). J. Cell. Physiol., 191, 95–104.

  • Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA and Steinman L . (2000). Proc. Natl. Acad. Sci. USA, 97, 2680–2685.

  • Wang T, Arifoglu P, Ronai Z and Tew KD . (2001). J. Biol. Chem., 276, 20999–21003.

  • Xu X, Lemaire C, Grzych JM, Pierce RJ, Raccurt M, Mullier F, Zerimech F, Decavel JP, Peyrol S, Liu J, Fontaine J, Lafitte S, Capron A and Cesbron JY . (1997). Infect. Immun., 65, 3867–3874.

  • Yin Z, Ivanov V, Habelhah H, Tew KD and Ronai Z . (2000). Cancer Res. (Adv. Brief), 60, 4053–4057.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kenneth D Tew.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Townsend, D., Tew, K. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369–7375 (2003). https://doi.org/10.1038/sj.onc.1206940

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206940

Keywords

  • GST
  • polymorphism
  • resistance
  • MAP kinase pathway

Further reading

Search

Quick links